Assertio Holdings, Inc. to Participate in the H.C. Wainwright BioConnect Virtual Conference
January 10 2022 - 8:00AM
Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ:
ASRT) today announced that the Company’s Chief Executive Officer,
Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will
participate in the H.C. Wainwright BioConnect Virtual Conference
scheduled to take place from Monday, January 10 through Thursday,
January 13, 2022. The Company’s investor presentation is now
available for on-demand viewing on the Assertio Investor Relations
website and will remain available on the Latest Events page for
approximately 30 days following the presentation.
To access the webcast and for more information about Assertio,
please visit
https://investor.assertiotx.com/overview/default.aspx.
About Assertio
Assertio is a leading commercial pharmaceutical company bringing
differentiated products to patients. The Company has a robust
portfolio of branded prescription products in three areas:
neurology, hospital, and pain and inflammation. Assertio has grown
through business development including licensing, mergers, and
acquisitions. To learn more visit www.assertiotx.com.
Investor Contact
Max NemmersHead, Investor Relations and Administration
investor@assertiotx.com
Forward Looking Statements
Statements in this communication that are not historical facts
are forward-looking statements that reflect Assertio’s current
expectations, assumptions and estimates of future performance and
economic conditions. These forward-looking statements are made in
reliance on the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”), and
Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements relate to, among other things,
future events or the future performance or operations of Assertio.
All statements other than historical facts may be forward-looking
statements and can be identified by words such as “anticipate,”
‘believe,” “could,” “design,” “estimate,” “expect,” “forecast,”
“goal,” “guidance,” “imply,” “intend,” “may,” “objective,”
“opportunity,” “outlook,” “plan,” “position,” “potential,”
“predict,” “project,” “prospective,” “pursue,” “seek,” “should,”
“strategy,” “target,” “would,” “will,” “aim” or other similar
expressions that convey the uncertainty of future events or
outcomes are used to identify forward-looking statements. Such
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and other factors, some of
which are beyond the control of Assertio.
Forward-looking statements involve inherent risks and
uncertainties that could cause actual results to differ materially
from those projected or anticipated, including risks related to the
offering. These risks are more fully described in Assertio’s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and in other
filings Assertio makes with the SEC from time to time. Investors
and potential investors are urged not to place undue reliance on
forward-looking statements in this communication, which speak only
as of this date. While Assertio may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to update or revise any
forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be
required by applicable law. Nothing contained herein constitutes or
will be deemed to constitute a forecast, projection or estimate of
the future financial performance or expected results of
Assertio.
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2024 to May 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From May 2023 to May 2024